🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum

RecruitingPhase 1, Phase 2Ages 20 Years - anyAllNational Taiwan University Hospital
NCT05325099 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Acute kidney injury (AKI) is increasing worldwide in recent years and is a major risk factor of chronic kidney disease (CKD). AKI, acute kidney disease (AKD) and CKD form a continuum whereby initial kidney injury leads to ongoing renal injury and eventually end-stage renal disease if no effective treatment is applied. Nevertheless, there are no useful pharmacotherapies approved clinically for the treatment of AKI and subsequent CKD. Previous studies of the investigators have confirmed that pericytes are the primary cell source of scar-producing myofibroblasts. Furthermore, the investigators had demonstrated that significant epigenetic modification in transcriptome analysis of pericytes develops in different stage of AKI-CKD continuum. These epigenetic memory made pericytes obtain proliferative and pro-fibrotic phenotypes in activated status and persist in inactivated status. Demethylati

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient with cardiac surgery associated-AKI, stage 2 and stage 3 Exclusion Criteria: * Chronic kidney disease * Decompensated heart failure (EF \< 45%) * Liver cirrhosis, child B or C * Acute infection * Acute bleeding * Long-term use of immunosuppressant other than azacitidine * Patients with active cancer other than acute leukemia or myelodysplastic syndrome * Leukopenia, anemia or thrombocytopenia * Pregnancy
💊

What it tests

  • Azacitidine
  • Placebo
📍

Where

1 site
Yu Hsiang Chou
Taipei, Taiwan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy